Matthew J. O’Brien, MD, MSc

Articles by Matthew J. O’Brien, MD, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

ByDavid T. Liss, PhD,Manisha Cherupally, MS,Matthew J. O’Brien, MD, MSc,Raymond H. Kang, MA,Cassandra Aikman, MPH,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Eleena Koep, MS,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

December 12th 2023

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

ByDavid T. Liss, PhD,Raymond H. Kang, MA,Nicola Lancki, MPH,Matthew J. O’Brien, MD, MSc,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Sterling A. Harris, BA,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

March 9th 2021

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

Latest Updated Articles

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications
Published: March 9th 2021 | Updated:
Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes
Published: December 12th 2023 | Updated:

Matthew J. O’Brien, MD, MSc

Articles by Matthew J. O’Brien, MD, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

Latest Updated Articles

Trending on AJMC

Investigating the Role of Gut Microbiota in IPF

Cost, Access Barriers Limit Women’s Use of Heart Monitors: Lindsey Valenzuela, PharmD